Delving into the Latest Updates on SP-1000 with Synapse

Overview

Basic Info

Drug Type

Unknown

Synonyms

Target

Cholesterol

Mechanism

Cholesterol inhibitors

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Hypercholesterolemia

Originator Organization

Georgetown University

Active Organization-

Inactive Organization

Samaritan Pharmaceuticals, Inc.

Drug Highest PhaseDiscontinuedPreclinical

First Approval Date-

Regulation-

AbstractBackgroundThe EDGE SP1000 is a newly developed single‐port (SP) robotic surgical system whose clinical evaluation in gynaecology has not yet been addressed.MethodsThis is a single‐arm clinical trial evaluating the perioperative outcomes of patients receiving EDGE SP1000 assisted surgeries. Patients with either benign or malignant gynaecological diseases suitable for robotic surgery were included, and their data were prospectively collected.ResultsEighteen patients were included and 8 of them had malignant conditions. The total operative time was 190.1 ± 83.3 min for benign diseases and 254.4 ± 59.4 min for malignant diseases. The mean estimated blood loss was 25 mL (range, 5–100). No assistant ports or conversions were required. No perioperative complications occurred. Overall satisfaction with the umbilical wounds was expressed at the 1‐month follow‐up.ConclusionEDGE SP1000 SP robotic surgical system is technically feasible and safe in various gynaecological surgeries with good cosmetic effects.

100 Deals associated with SP-1000

Login to view more data